Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(19 sites)
China
Anhui Provincial Cancer Hospital, Hefei, Anhui Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing Municipality Gansu Cancer Hospital, Lanzhou, Gansu Guangxi Zhuang Autonomous Region Cancer Hospital (Affiliated Cancer Hospital of Guangxi Medical University), Nanning, Guangxi The First Affiliated Hospital of Hebei North University, Shijiazhuang, Hebei Tianjin Cancer Hospital, Tianjin, Hebei Henan Cancer Hospital, Zhengzhou, Henan The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Hubei Cancer Hospital, Wuhan, Hubei Hunan Cancer Hospital, Changsha, Hunan Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University, Nanjing, Jiangsu Jiangsu North People's Hospital, Yangzhou, Jiangsu Liaoning Cancer Hospital and Institute, Shenyang, Liaoning The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shanxi Shanxi Provincial Tumor Hospital, Xi’an, Shanxi Tianjin People's Hospital, Tianjin, Tianjin Municipality The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang